NVS has been the topic of several other research reports. Zacks Investment Research cut shares of Novartis AG from a hold rating to a sell rating in a report on Wednesday, September 21st. JPMorgan Chase & Co. reaffirmed a buy rating on shares of Novartis AG in a report on Tuesday, September 13th. Argus reaffirmed a hold rating on shares of Novartis AG in a report on Thursday, August 25th. Chardan Capital reduced their target price on shares of Novartis AG from $95.00 to $92.00 and set a buy rating on the stock in a report on Monday, October 10th. Finally, Bank of America Corp. reaffirmed a hold rating on shares of Novartis AG in a report on Tuesday, July 12th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of Hold and an average target price of $91.33.
Shares of Novartis AG (NYSE:NVS) opened at 76.09 on Friday. The stock has a market capitalization of $181.19 billion, a PE ratio of 27.17 and a beta of 0.57. Novartis AG has a 52-week low of $69.90 and a 52-week high of $94.63. The firm has a 50-day moving average of $79.33 and a 200 day moving average of $78.96.
Novartis AG (NYSE:NVS) last issued its earnings results on Tuesday, July 19th. The company reported $1.23 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.18 by $0.05. The firm had revenue of $12.47 billion for the quarter, compared to analysts’ expectations of $12.33 billion. Novartis AG had a net margin of 13.84% and a return on equity of 15.33%. During the same quarter last year, the company earned $1.25 earnings per share. Equities research analysts forecast that Novartis AG will post $4.72 EPS for the current fiscal year.
Several institutional investors have recently made changes to their positions in NVS. Primecap Management Co. CA boosted its position in shares of Novartis AG by 0.8% in the first quarter. Primecap Management Co. CA now owns 20,938,858 shares of the company’s stock worth $1,516,811,000 after buying an additional 170,750 shares during the last quarter. Fisher Asset Management LLC boosted its position in shares of Novartis AG by 1.2% in the second quarter. Fisher Asset Management LLC now owns 6,363,641 shares of the company’s stock worth $523,791,000 after buying an additional 76,542 shares during the last quarter. Loomis Sayles & Co. L P boosted its position in shares of Novartis AG by 6.8% in the second quarter. Loomis Sayles & Co. L P now owns 5,601,211 shares of the company’s stock worth $462,156,000 after buying an additional 358,263 shares during the last quarter. Mawer Investment Management Ltd. boosted its position in shares of Novartis AG by 10.4% in the second quarter. Mawer Investment Management Ltd. now owns 3,743,858 shares of the company’s stock worth $308,906,000 after buying an additional 351,773 shares during the last quarter. Finally, Parnassus Investments CA boosted its position in shares of Novartis AG by 61.3% in the second quarter. Parnassus Investments CA now owns 3,481,896 shares of the company’s stock worth $287,291,000 after buying an additional 1,323,724 shares during the last quarter. 9.78% of the stock is currently owned by institutional investors and hedge funds.
About Novartis AG
Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.